News

BTL Enhances EMSELLA Platform with New Versatile Benefits

BTL Enhances EMSELLA Platform with New Versatile Benefits

BTL's Commitment to Pelvic Health Innovation

BTL, a pioneer in non-invasive medical solutions, is excited to share significant advancements regarding its EMSELLA platform. With the recent expansion of its Health Canada License, BTL continues to solidify its position at the forefront of pelvic health and intimate wellness. The EMSELLA platform, which has already made waves in the market for its capability to treat urinary incontinence in both men and women, has now gained additional approvals to enhance sexual function, particularly in those experiencing disorders linked to weak pelvic floor muscles.

Understanding EMSELLA's Unique Capabilities

The EMSELLA platform is FDA cleared and licensed by Health Canada, highlighting its robust clinical efficacy for treating urinary incontinence. The recent enhancements expand its capabilities, ensuring patients have access to a comprehensive solution for intimate wellness. The platform addresses not just incontinence but also the critical area of sexual health, which often remains under-discussed. Such advancements not only benefit individual patients but also empower healthcare providers to deliver effective treatments.

Impressive Clinical Outcomes

Backed by compelling clinical research, EMSELLA is redefining non-invasive care in the realm of pelvic health and sexual function. Patients are reporting significant improvements in various aspects of their sexual health. Some key findings include:

Impact on Sexual Satisfaction:

  • A remarkable 76% improvement in sexual satisfaction and desire has been noted among users.
  • 60% of patients reported an enhancement in the quality of orgasms.
  • Over a third, approximately 37%, experienced better maintenance of erection during intercourse.
  • Patients have shown a significant 48% improvement in pelvic muscle endurance.

These statistics illustrate how EMSELLA not only tackles urinary issues but also contributes to overall sexual wellness. In comparison to conventional methods, EMSELLA stands out, being reported as seven times more effective than traditional pelvic floor muscle training.

What Experts Are Saying

David Chmel, CEO of BTL North America, has expressed confidence in the EMSELLA platform, stating, "EMSELLA continues to exceed expectations—delivering results that enhance life quality, confidence, and well-being in a manner that is both comfortable and non-invasive." This sentiment is echoed by professionals in the field, such as Dr. Shari Caplan. A board-certified expert in functional and integrative medicine, Dr. Caplan notes, "We are observing a significant evolution in the management of pelvic and sexual health. The results offered by EMSELLA are remarkable, with many patients achieving outcomes previously only obtainable through surgical intervention or long-term therapy. This innovative device has become essential in my practice for treating urinary control issues and promoting sexual wellness amongst both genders."

The Growing Demand for Intimate Wellness Solutions

As awareness of intimate wellness treatment options increases, EMSELLA has emerged as a vital tool for addressing these often-sensitive health concerns. Its versatility and proven efficacy make it an invaluable addition to any clinical practice aimed at improving patients' quality of life. The rise in demand reinforces BTL's commitment to providing modern, effective solutions that prioritize patient comfort and accessibility. As the landscape of pelvic health treatment continues to evolve, BTL's EMSELLA platform is set to remain at the forefront of these advancements.

Frequently Asked Questions

1. What does the EMSELLA platform treat?

The EMSELLA platform is designed to treat urinary incontinence and enhance sexual health through non-invasive technology.

2. How does EMSELLA compare to traditional therapies?

EMSELLA is reported to be seven times more effective than traditional pelvic floor muscle training methods.

3. What are some clinical outcomes reported by patients?

Many patients report significant improvements in sexual satisfaction, orgasm quality, and pelvic muscle endurance after using EMSELLA.

4. Who can benefit from EMSELLA treatments?

Both men and women experiencing urinary incontinence and sexual health issues can benefit from EMSELLA treatments.

5. Is EMSELLA a comfortable treatment option?

Yes, EMSELLA treatments are designed to be comfortable and non-invasive, making them accessible and easy for patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 120

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 99

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 710

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Onodrim Raises $300M to Propel EU Defence Future

Updated Category News Views 20

Onodrim Industries' Bold Bid to Reshape European Security Right out of the gate, Onodrim Industries is thundering onto the scene with a hefty $300 million Series A round to flex its muscles across Europe's defence and industrial sectors. This ain't your run-of-the-mill startup story. This is about flexing hard-earned capital to snap up established players and inject a...

Continue Reading
Wuliangye Aims for Global Branding Boost at Panda Event

Updated Category News Views 179

Wuliangye Takes Center Stage at Global Event Everyone's chasing that global branding magic, but here's Wuliangye strutting its stuff at the Global Panda Partners Conference. Held in Sichuan Province from November 2 to 4, this is not just another show; it's a bold move from the Chinese baijiu maker to push the 'harmony and coexistence' mantra on the world stage. Not just...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 312

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
KT&G Launches Heated Tobacco in Kazakhstan's Market

Updated Category News Views 43

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 474

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
AI Shopping Surge: WeFetch.ai's Bold Rebrand Move

Updated Category News Views 134

Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Traditions Bancorp Declares New Cash Dividend for Investors

Updated Category News Views 76

Traditions Bancorp Declares Quarterly Cash Dividend On a recent date, the Board of Directors of Traditions Bancorp (OTC: TRBK), the parent company of Traditions Bank, announced a quarterly cash dividend of eight cents per common share. This dividend reflects the company's strong commitment to returning value to its shareholders and will be disbursed shortly. The payment...

Continue Reading
LONGi BC Tech Paves the Way for Solar Leadership in Europe

Updated Category News Views 334

LONGi's Impact on Europe's Solar Industry LONGi, recognized as a leader in solar technology, has made remarkable strides in reshaping the renewable energy scene in Europe. With an impressive 10GW of back contact (BC) modules deployed, the continent is rapidly becoming a hotbed for high-efficiency solar solutions. This accomplishment underlines the company's crucial...

Continue Reading
PACS Group Investors: Important Actions to Take Now

Updated Category News Views 152

Important Deadline for PACS Group Investors Investors in PACS Group, Inc. are advised to take note of an important lead plaintiff application deadline related to recent securities class action lawsuits. If you have incurred losses exceeding $100,000 in the company's stock, you may be eligible to participate in these legal proceedings. Class Action Lawsuit Details The...

Continue Reading
Exploring Market Sentiment Around Morningstar Inc and Its Trends

Updated Category News Views 207

Understanding Morningstar Inc's Market Position Morningstar Inc (NYSE:MORN) has recently shown a notable decline in its short interest, with a decrease of 9.22% reported. Currently, there are approximately 655 thousand shares sold short, constituting about 2.56% of the total shares available for trading. This information is pivotal for investors since it reflects the...

Continue Reading
Julie Springer Expands Legal Services with Mediation Practice

Updated Category News Views 363

Julie Springer's New Ventures in Mediation In the dynamic legal scene of Austin, seasoned attorney Julie A. Springer is making waves by broadening her practice to include mediation and arbitration services. This thoughtful transition reflects her long-time dedication to effectively settling business disputes, educational conflicts, and employment issues. Professional...

Continue Reading